ROS and SDT are both important areas of focus in immuno-oncology. ROS play dual roles in cancer, contributing to both tumor progression and therapy-induced tumor cell death. Harnessing ROS through therapies like SDT offers a promising avenue for selectively targeting and destroying cancer cells, especially when combined with other immunotherapeutic approaches. SDT, with its non-invasive nature and potential for deep tissue targeting, is an emerging modality that holds significant promise in the treatment of various cancers, particularly when combined with strategies that enhance the immune response.